Table 4 Association between the incidence of co-morbidity in 11 139 ovarian cancer patients and 55 687 controls estimated by hazard ratios (HRs) and confidence intervals (CIs)

From: Evaluation of prevalent and incident ovarian cancer co-morbidity

 

All years of follow-up a

First year of follow-up b

Excluding prevalent cases c

 

Cases/controls

HR

95% CI

Cases/controls

HR

95% CI

Cases/controls

HR

95% CI

Haematologic complications

1253/1384

8.6

(7.9–9.3)

729/186

23.4

(19.9–27.6)

1144/1285

8.8

(8.0–9.5)

Thyroid disease

197/1122

1.8

(1.5–2.0)

93/150

3.7

(2.9–4.8)

129/969

1.4

(1.2–1.7)

Cardiovascular disease

1219/7630

1.6

(1.5–1.7)

536/1495

2.2

(2.0–2.4)

773/5429

1.5

(1.4–1.6)

Cerebrovascular event

357/3156

1.2

(1.1–1.3)

114/442

1.6

(1.3–2.0)

320/2814

1.2

(1.1–1.4)

Thromboembolic events

824/959

7.9

(7.1–8.7)

391/152

14.9

(12.3–18.1)

743/882

7.9

(7.1–8.7)

Hypertension

911/5544

1.7

(1.5–1.8)

100/331

1.8

(1.4–2.2)

514/4530

1.3

(1.2–1.4)

Pulmonary disease

281/1628

1.6

(1.4–1.8)

3/17

1.1

(0.3–3.6)

234/1289

1.9

(1.6–2.1)

GI complications

1938/2436

7.2

(6.8–7.7)

762/486

9.2

(8.2–10.3)

1647/1936

8.2

(7.7–8.8)

Diabetes mellitus

507/2540

1.8

(1.6–2.0)

280/544

3.1

(2.7–3.6)

231/1704

1.4

(1.2–1.6)

Liver/pancreatic disease

99/605

1.6

(1.3–2.0)

32/84

2.3

(1.5–3.4)

89/560

1.6

(1.3–2.0)

Urinary tract complications

207/631

3.3

(2.8–3.9)

75/93

5.0

(3.6–6.8)

193/571

3.6

(3.0–4.2)

Infectious complications

1055/3499

3.0

(2.8–3.2)

459/505

5.4

(4.8–6.2)

959/3114

3.2

(3.0–3.5)

Neoplasms

124/512

2.4

(2.0–2.9)

44/72

3.5

(2.4–5.1)

369/3208

1.5

(1.3–1.6)

  1. Abbreviation: GI=gastrointestinal.
  2. aEnd of follow-up was the first date of an admission with the diagnosis of interest, date of death, date of ovarian cancer diagnosis for a control subject, or 31 December 2006, whichever came first.
  3. bFollow-up started 30 days after cancer diagnosis.
  4. cThe prevalence was defined as having one of the selected diseases either as a primary or as a secondary discharge diagnosis from 10 years before the ovarian cancer diagnosis up to 30 days after.
Back to article page